Intubating airway device

Information

  • Patent Grant
  • 10625037
  • Patent Number
    10,625,037
  • Date Filed
    Wednesday, December 17, 2014
    9 years ago
  • Date Issued
    Tuesday, April 21, 2020
    4 years ago
Abstract
An airway device for human or animal use includes an airway tube having a first end and a second end, the first end of which is surrounded by a laryngeal cuff configured to fit over the laryngeal inlet of a patient when in situ. The first end of the airway tube is provided with an intubating ramp configured to direct a tube inserted through the airway tube into the laryngeal inlet of the patient when in situ.
Description
FIELD OF THE INVENTION

The present invention relates to medical devices and is applicable to laryngeal airway devices and to their methods of manufacture. It is particularly applicable to devices used in the administration of Oxygen and/or anaesthetic gases to a human or veterinary patient breathing spontaneously, for Intermittent Positive Pressure Ventilation (IPPV) during a surgical procedure or resuscitation and for intubating patients during such procedures.


BACKGROUND TO THE INVENTION

GB2393399 (Nasir) describes an airway device comprising an airway tube having a first end and a second end, the first end of which is surrounded by a non-inflatable laryngeal cuff which forms an anatomical fit over the laryngeal inlet of a patient and a buccal cavity stabiliser located on or around the airway tube between the laryngeal cuff and the second end of the tube, the buccal stabiliser being adapted to prevent rotational or side-to-side movement of the airway device in use.


Whilst such airway devices provide a significant improvement over the use of inflatable cuff airway devices, it is still sometimes necessary to intubate a patient during a procedure.


A number of attempts have been made to provide for an airway device which not only forms an external seal around the laryngeal inlet of the patient, but also serves as a guide to allow for the insertion of an endotracheal tube. However, such devices have always been inflatable, do not always provide for the endotracheal tube to be guided directly into the laryngeal inlet and instead can direct the endotracheal tube into the oesophagus of the patient, and can cause the airway tube of the airway device to become blocked cutting off the air supply to the patient.


SUMMARY OF THE INVENTION

A first aspect of the present invention provides an airway device as described in the accompanying claims.


Accordingly, according to a first aspect of the present invention, there is provided an airway device for human or animal use comprising an airway tube having a first end and a second end, the first end of which is surrounded by a laryngeal cuff configured to fit over the laryngeal inlet of a patient when in situ, wherein the first end of the airway tube is provided with an intubating ramp configured to direct a tube inserted through the airway tube into the laryngeal inlet of the patient when in situ. Preferably the tube is an endotracheal tube.


In prior art devices such as that described in GB2393399 (Nasir), and as illustrated in FIG. 1, when an endotracheal tube is inserted through the airway tube, the endotracheal tube, instead of following its natural curve (which allows for correct insertion of the endotracheal tube into the laryngeal inlet), follows the curvature of the airway tube of the airway device. This often leads to the endotracheal tube, instead of entering the laryngeal inlet, sliding along the inside of the laryngeal cuff towards the tip of the device which can result in contact between the endotracheal tube and the larynx of the patient, and even insertion of the endotracheal tube into the oesophagus of the patient, both of which are undesirable.


However, in the present invention the airway device is provided with an intubating ramp which ensures that the endotracheal tube, when inserted through the airway tube, follows its natural curve, rather than the curve of the airway tube, and guides the endotracheal tube into the laryngeal inlet of the patient when the airway device is in situ in a patient.


Preferably the intubating ramp is provided on the internal wall of the dorsal side of the airway tube. In the alternative the intubating ramp is provided on the internal surface of the dorsal side of the laryngeal cuff. Preferably the ramp is angled to ensure that when the tube is inserted through the airway tube when the device is in situ in a patient, it exists the device higher up in the anatomy of the patient and is guided into the laryngeal inlet of the patient.


Preferably in addition to the intubation ramp, the first end of the airway tube is of greater diameter and thus wider than the remainder of the airway tube. In particular it is preferred that the internal surface of the ventral side of the airway tube is flattened rather than curved to provide this widening. This further enables the endotracheal tube, when inserted through the airway tube, to follow its natural curve, rather than the curve of the airway tube, and works in combination with the intubating ramp. Essentially what is created by the widening is a flaring at the first end of the airway tube as the airway tube emerges into the rear of the cuff.


Preferably the intubating ramp is provided with a channel or groove. Preferably the channel or groove runs longitudinally along the full length of the intubating ramp from the first end to the second end of the longitudinal ramp. More preferably the intubating ramp is provided with a plurality of channels or grooves. The provision of the intubating ramp reduces the depth of the internal cavity of the laryngeal cuff, this means that should the device be sub-optimally inserted that there is risk that the airway of the patient could become partially occluded. The provision of the one or more channel(s) or groove(s) ensures the patency of the airflow through the airway device into the airway of the patient without compromising the effect of the ramp.


Preferably the tip of the laryngeal cuff is elongate. Preferably the tip of the laryngeal cuff is provided with a protrusion or bump on the back dorsal side thereof. The elongate nature of the tip of the laryngeal cuff along with the dorsal protrusion or bump both assist to provide an improved oesophageal seal when the airway device is in situ in the patient. By providing an improved oesophageal seal there is reduced risk of inflation of the stomach of the patient, and a reduced risk of regurgitation entering into the airway of the patient.


Preferably a side wall of the second end of the airway tube is provided with a supplementary gas inlet. The supplementary gas inlet allows for additional oxygen or other gas to be provided to the patient if required. A suitable supplementary gas inlet has been described in WO2011131974 (Miller).


Preferably the cuff is non-inflatable and is pre-formed in a shape adapted to form an anatomical fit over the laryngeal framework of a patient.


Preferably the laryngeal cuff is pre-formed, pre-inflated with air or pre-filled with a suitable fluid. Most preferably the laryngeal cuff is non-inflatable, however in the alternative the laryngeal cuff can be inflatable.


In one alternative the airway device further comprises a buccal cavity stabiliser located on or around the airway tube between the laryngeal cuff and the second end of the tube. The buccal cavity stabiliser, if provided, may be formed from the same material as the cuff or from a different material and assists in locating and maintaining the position of the device in use.


In a particularly preferred embodiment the buccal cavity stabiliser, if provided, is formed as an integral part of the airway tube, and further preferably the buccal cavity stabiliser, the airway tube and the laryngeal cuff are all formed as an integral unit.


In a further alternative no buccal cavity stabiliser is provided.


The Shore hardness of the various, parts, portions or components is an important feature of the invention. For example, the laryngeal cuff is preferably formed from a material with a Shore hardness on the A scale of 40 or less and more preferably 000 to 20, and most preferably 000 to 4.


Preferably the laryngeal cuff and a front, ventral part of the buccal cavity stabiliser, if provided, are formed from a material of substantially the same Shore hardness. This simplifies construction and ensures that all portions of the device that come into firm contact with the patient's soft tissue are relatively soft.


In a further preferred embodiment a back or dorsal part of the device and a front or ventral part of the device are formed from materials of different Shore hardness. This enables the dorsal portion to be made of a firmer material than the ventral portion.


Preferably the back or dorsal part of the device is formed from a material of Shore hardness less than 60 on the A scale, more preferably 25 to 45, and most preferably 30 to 40.


Preferably the device further incorporates a gastric tube passageway extending from the tip of the cuff to the second end of the airway device.


According to a second aspect of the invention there is provided an airway device for human or animal use comprising an airway tube having a first end and a second end, the first end of which is surrounded by a laryngeal cuff configured to fit over the laryngeal inlet of a patient when in situ, wherein the first end of the airway tube is of widened diameter or flared.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described, by way of example only, with reference to the accompanying drawings in which:



FIG. 1 illustrates a part cross-sectional view of the laryngeal cuff of the prior art;



FIG. 2 illustrates a part cross-sectional view of the laryngeal cuff according to a first embodiment;



FIG. 3 illustrates a front ventral perspective view of the laryngeal cuff according to a first embodiment;



FIG. 4 illustrates a side view of the laryngeal cuff according to a first embodiment;



FIG. 5 illustrates a back dorsal view of the laryngeal cuff according to a first embodiment;



FIG. 6 illustrates a side view of the supplementary gas inlet according to a first embodiment; and



FIG. 7 illustrates a side view of the airway device according to a first embodiment.





DESCRIPTION OF THE PREFERRED EMBODIMENTS

Embodiments of the present invention are described below by way of example only. These examples represent the best ways of putting the invention into practice that are currently known to the applicant although they are not the only ways in which this could be achieved.


Referring to FIGS. 2 to 7, these illustrate an airway device 10 according to a first embodiment of the invention. The airway device 10 has an airway tube 12 having a first end 14 and a second end 16. The second end 16 optionally terminates in a 15 mm or other connector 18 suitable for connection to an anaesthetic breathing system of conventional type. Formed around the first end 14 of the airway tube is a laryngeal cuff 20. In the embodiment illustrated the laryngeal cuff 20 is non inflatable and is adapted in its shape and contours to correspond with the laryngeal inlet region of a patient.


The first end 14 of the airway tube 12 is also provided with an intubating ramp 22 configured to direct an endotracheal tube (or another other applicable tube or device) inserted through the airway tube 12 into the laryngeal inlet of the patient when the airway device 10 is in situ within a patient. The intubating ramp 22 ensures that the endotracheal tube, when inserted through the airway tube, follows its natural curve, rather than the curve of the airway tube 12, and guides the endotracheal tube into the laryngeal inlet of the patient when the airway device 10 is in situ in a patient.


In the embodiment illustrated the intubating ramp 2 is provided on the internal wall of the back dorsal side of the airway tube 12. In the alternative the intubating ramp 22 can instead be provided on the internal surface of the back dorsal side of the laryngeal cuff 20.


In addition to the provision of intubating ramp 22, the first end 14 of the airway tube 12 is of greater diameter and thus wider than the remainder of the airway tube 12. In the embodiment illustrated the internal surface of the front ventral side 24 of the airway tube 12 is flattened rather than curved to provide this widening. This further enables the endotracheal tube, when inserted through the airway tube 12, to follow its natural curve, rather than the curve of the airway tube 12 and works in combination with the intubating ramp 22.


In the embodiment illustrated the intubating ramp 22 is optionally provided with two channels 26, 28 that run longitudinally along the full length of the intubating ramp 22 from the first end to the second end thereof. The provision of the intubating ramp 22 reduces the depth of the internal cavity of the laryngeal cuff 20, this means that should the airway device 10 be sub-optimally inserted that there is risk that the airway of the patient could become partially occluded. The provision of the channels 26, 28 ensures the patency of the airflow through the airway device 10 into the airway of the patient without compromising the effect of the intubating ramp 22.


In the embodiment illustrated the tip 30 of the laryngeal cuff 20 is elongate compared to the prior art device illustrated in FIG. 1. In addition the tip 30 of the laryngeal cuff 20 is provided with a protrusion or bump 32 on the back dorsal side thereof. The elongate nature of the tip 30 of the laryngeal cuff 20 along with the dorsal protrusion or bump 32 both assist to provide an improved oesophageal seal when the airway device 10 is in situ in the patient. By providing an improved oesophageal seal there is reduced risk of inflation of the stomach of the patient, and a reduced risk of regurgitation entering into the airway of the patient.


In addition in the embodiment illustrated a side wall of the second end 16 of the airway tube 12 has been provided with an optional supplementary gas inlet 34, more particularly the supplementary gas inlet 34 is formed as part of connector 18, however in the alternative it may be separate from connector 18. The supplementary gas inlet 34 allows for additional oxygen or other gas to be provided to the patient if required.


In one alternative the laryngeal cuff is non-inflatable and is formed from any suitable soft plastics material. By way of a preferred softness (hardness) range, on the Shore A scale of Hardness, a hardness of less than 40 for the face of the laryngeal cuff that contacts the laryngeal inlet is optimum. By way of a preferred range, a value on the same scale of 000 to 20 is preferred, with a particularly preferred range of 000 to 4. The softness of the laryngeal cuff can be further adapted by forming cavities or channels within the body of the cuff itself.


In a further alternative the laryngeal cuff may be pre-filled with a fluid such as air, or other non-toxic gas, or a non-toxic liquid. In this context the term fluid has a broad meaning and includes any suitable gas, liquid, vapour or combination thereof and will be determined and designed by an expert in this field of anatomy/anaesthesia in conjunction with the materials specialist. The laryngeal cuff will be constructed of such a material which will not allow nitrous oxide (anaesthetic gas) to diffuse through the material to any significant amount so that the extra luminal pressure is kept constant. It follows therefore that the laryngeal cuff should be substantially impermeable to the fluid with which is filled and to anaesthetic gases.


Alternatively, the laryngeal cuff can be formed from a soft, foamed material or can be foam filled. In either case this provides a soft deformable but shaped surface around the face of the laryngeal cuff to engage over the anatomy of the larynx inlet region. Such a foam filled device will minimise any potential damage to the structures in that region whilst still providing a substantially complete seal.


Further in the alternative the laryngeal cuff is pre-filled during manufacture with a fluid in which case the lining of the cuff should be made from a material that does not absorb anaesthetic gases such as Nitrous Oxide, such that the pressure inside the cuff does not rise during use.


In another alternative the laryngeal cuff may be formed from a material which is adapted to absorb a liquid, such as water, mucous or blood or similar liquid material and in doing so to swell in size so as to confirm to the anatomical mucocartilagenous framework of the patient's laryngeal inlet. Such materials will be selected by the materials specialist but include CRM (cotton rayon mixes) as used in TAMPAX® tampons, or compressed Gel Foam 5.


In a further, alternative, the laryngeal cuff could take the form of a conventional, inflatable laryngeal cuff. The technology to form an inflatable laryngeal cuff is well known and need not be described here.


Finally, in yet another alternative, the laryngeal cuff may be hollow, but not inflatable in the traditional sense of the word, and instead Positive Pressure Ventilation is employed to “inflate” and self-pressurise the laryngeal cuff.


Also in the embodiment illustrated a buccal cavity stabiliser 36 has been provided around the airway tube 12 between the laryngeal cuff 20 and the second end 16 of the airway tube 12. The buccal cavity stabiliser 36 assists in locating and maintaining the position of the airway device 10 in use.


In the embodiment illustrated the buccal cavity stabiliser 36 is formed as an integral part of the airway tube 12, and further preferably the buccal cavity stabiliser 38, the airway tube 12 and the laryngeal cuff 20 are all formed as an integral unit.


In an alternative, no buccal cavity stabiliser 36 is provided.


A gastric tube passageway 38, separate to the airway tube 12 is provided which runs from an opening in the second end of the device near the connector 18 if provided to an opening in the tip of the cuff 20. The gastric tube passageway 38 allows for any gastric aspirate to be detected in the event of passive regurgitation during use. It also provides a route for the insertion of small-bore gastric tubes (e.g., Freka Tubes).


The device may be constructed from any suitable plastics material as selected by the materials specialist. Latex-free medical grade silicone rubber is one preferred material. The cuff should be soft in texture to avoid undue damage to the surrounding tissue. Other suitable materials for construction of this type of device include, but are not limited to, Poly Vinyl Chloride (PVC), Thermoplastic Elastomers such as the styrenic block copolymers (eg Styrene Butadiene Styrene (SBS), Styrene Ethylene Butylene Styrene (SEBS)), and Thermoplastic Olefin Blends (TPO), Thermoplastic PolyUrethanes (TPU), Copolyester (COPE), Polyether Block Amides (PEBAX) and foamed versions thereof, where appropriate.


A further important factor involved in the choice of a suitable material is transparency. Ideally the material or materials of construction should be substantially clear or transparent. This enables the anaesthetist or operator to see the inner lumen of the airway to check for blockages or other problems. Such transparent materials are known to the materials specialist.

Claims
  • 1. An airway device for human or animal use comprising an airway tube having a first end and a second end, wherein the first end of the airway tube is surrounded by a laryngeal cuff configured to fit over a laryngeal inlet of a patient when in situ, wherein the first end of the airway tube is provided with an intubating ramp disposed on an inner wall of the airway tube, the intubating ramp having a first end and a second end configured to direct a tube inserted through the airway tube into the laryngeal inlet of the patient when in situ, wherein the first end of the airway tube is of greater diameter than a remainder of the airway tube, and wherein an internal wall of the airway tube is curved other than a section of a ventral side of the airway tube, which section is flattened.
  • 2. An airway device as claimed in claim 1 wherein the intubating ramp is provided on an internal wall of a dorsal side of the airway tube.
  • 3. An airway device as claimed in claim 1 wherein the intubating ramp is provided with a channel.
  • 4. An airway device as claimed in claim 3 wherein the channel runs longitudinally along the full length of the intubating ramp from the first end to the second end of the intubating ramp.
  • 5. An airway device as claimed in claim 3 wherein the intubating ramp is provided with a plurality of channels.
  • 6. An airway device as claimed in claim 1 wherein the laryngeal cuff has an elongate tip.
  • 7. An airway device as claimed in claim 1 wherein a tip of the laryngeal cuff is provided with a protrusion on a back dorsal side thereof.
  • 8. An airway device as claimed in claim 1 where a side wall of the second end of the airway tube is provided with a supplementary gas inlet.
Priority Claims (1)
Number Date Country Kind
1322328.4 Dec 2013 GB national
PCT Information
Filing Document Filing Date Country Kind
PCT/GB2014/053744 12/17/2014 WO 00
Publishing Document Publishing Date Country Kind
WO2015/092404 6/25/2015 WO A
US Referenced Citations (192)
Number Name Date Kind
478582 Ermold Jul 1892 A
2099127 Leech Nov 1937 A
3443564 Oehmig May 1969 A
3616799 Sparks Nov 1971 A
3734100 Walker et al. May 1973 A
3968800 Vilasi Jul 1976 A
3995643 Merav Dec 1976 A
4509514 Brain Apr 1985 A
4846791 Hattler Jul 1989 A
4913139 Ballew Apr 1990 A
4919126 Baildon Apr 1990 A
4987895 Heimlich Jan 1991 A
4995388 Brain Feb 1991 A
5054483 Marten et al. Oct 1991 A
5174283 Parker Dec 1992 A
5181505 Lew Jan 1993 A
5241956 Brain Sep 1993 A
5249571 Brain Oct 1993 A
5259371 Tonrey Nov 1993 A
5282464 Brain Feb 1994 A
5285778 Mackin Feb 1994 A
5297547 Brain Mar 1994 A
5303697 Brain Apr 1994 A
5305743 Brain Apr 1994 A
5309906 LaBombard May 1994 A
5322062 Servas Jun 1994 A
5339805 Parker Aug 1994 A
5355879 Brain Oct 1994 A
5391248 Brain Feb 1995 A
5477851 Callaghan et al. Dec 1995 A
5584290 Brain Dec 1996 A
5605149 Wafters Feb 1997 A
5618267 Palestrant Apr 1997 A
5623921 Kinsinger et al. Apr 1997 A
5632271 Brain May 1997 A
5653229 Greenberg Aug 1997 A
5655519 Alfery Aug 1997 A
5682880 Brain Nov 1997 A
5711293 Brain Jan 1998 A
5791341 Bullard Aug 1998 A
5827243 Palestrant Oct 1998 A
5853004 Goodman Dec 1998 A
5865176 O'Neil Feb 1999 A
5878745 Brain Mar 1999 A
5881726 Neame Mar 1999 A
5896858 Brain Apr 1999 A
5915383 Pagan Jun 1999 A
5921988 Legrand Jul 1999 A
5937859 Augustine et al. Aug 1999 A
5937860 Cook Aug 1999 A
5964217 Christopher Oct 1999 A
5976072 Greenberg Nov 1999 A
5979445 Neame et al. Nov 1999 A
5988167 Kamen Nov 1999 A
6003514 Pagan Dec 1999 A
6055984 Brain May 2000 A
6070581 Augustine et al. Jun 2000 A
6079409 Brain Jun 2000 A
D429811 Bermudez Aug 2000 S
6095144 Pagan Aug 2000 A
6152136 Pagan Nov 2000 A
6216696 van den Berg Apr 2001 B1
6280675 Legrand Aug 2001 B1
6311688 Augustine et al. Nov 2001 B1
6318367 Mongeon Nov 2001 B1
6422239 Cook Jul 2002 B1
6439232 Brain Aug 2002 B1
6474332 Arndt Nov 2002 B2
6536437 Dragisic Mar 2003 B1
6604525 Pagan Aug 2003 B2
6631720 Brain Oct 2003 B1
D482118 Dave et al. Nov 2003 S
6672305 Parker Jan 2004 B2
6679263 Luchetti et al. Jan 2004 B2
6698430 Van Landuyt Mar 2004 B2
6705318 Brain Mar 2004 B1
6705321 Cook Mar 2004 B2
6705322 Chang Mar 2004 B2
6792948 Brain Sep 2004 B2
6799574 Collins Oct 2004 B1
6827710 Mooney Dec 2004 B1
6877512 Imai et al. Apr 2005 B2
6918388 Brain Jul 2005 B2
6918391 Moore Jul 2005 B1
6971382 Corso Dec 2005 B1
7004169 Brain Feb 2006 B2
D518572 Nasir Apr 2006 S
D518890 Nasir Apr 2006 S
7040312 Alfery et al. May 2006 B2
7040322 Fortuna May 2006 B2
7047973 Chang May 2006 B2
7096868 Tateo et al. Aug 2006 B2
7097802 Brain Aug 2006 B2
7134431 Brain Nov 2006 B2
7140368 Collins Nov 2006 B1
D542675 Luxton et al. May 2007 S
7263998 Miller Sep 2007 B2
RE39938 Brain Dec 2007 E
7305985 Brain Dec 2007 B2
7357845 Cook Apr 2008 B2
7506648 Brain Mar 2009 B2
D611138 Nasir Mar 2010 S
D615188 Nasir May 2010 S
D618788 Dubach Jun 2010 S
7762261 Fortuna Jul 2010 B1
7784464 Cook Aug 2010 B2
7806119 Nasir Oct 2010 B2
7896007 Brain Mar 2011 B2
7900632 Cook Mar 2011 B2
7934502 Cook May 2011 B2
8001964 McDonald et al. Aug 2011 B2
D650520 Timmermans Dec 2011 S
8091242 Teys et al. Jan 2012 B2
8215307 Nasir Jul 2012 B2
D665495 Nasir Aug 2012 S
D668759 Nasir Oct 2012 S
D693920 Miller Nov 2013 S
D710990 Brain Aug 2014 S
8809682 Hepfinger Aug 2014 B2
D716937 Brain Nov 2014 S
9265905 Aslam Feb 2016 B2
D791305 Poulsen Jul 2017 S
D809125 Kheong Jan 2018 S
20010015207 Pagan Aug 2001 A1
20010025641 Doane et al. Oct 2001 A1
20010027793 Tielemans Oct 2001 A1
20020010417 Bertram Jan 2002 A1
20020010617 Hamaguchi et al. Jan 2002 A1
20020078961 Collins Jun 2002 A1
20020103472 Kramer Aug 2002 A1
20020108610 Christopher Aug 2002 A1
20020112728 Landuyt Aug 2002 A1
20020170556 Gaitini Nov 2002 A1
20030037790 Brain Feb 2003 A1
20030066532 Gobel Apr 2003 A1
20030101998 Zocca et al. Jun 2003 A1
20030136413 Brain et al. Jul 2003 A1
20030172925 Zocca et al. Sep 2003 A1
20030172933 Nimmo Sep 2003 A1
20030213492 Alfery Nov 2003 A1
20040020488 Kniewasser Feb 2004 A1
20040020491 Fortuna Feb 2004 A1
20040060564 Brain Apr 2004 A1
20040200479 Chang Oct 2004 A1
20050016529 Cook Jan 2005 A1
20050051173 Brain Mar 2005 A1
20050051175 Brain Mar 2005 A1
20050066975 Brain Mar 2005 A1
20050081861 Nashir Apr 2005 A1
20050103345 Brain May 2005 A1
20050104255 Mejlhede et al. May 2005 A1
20050199244 Tateo Sep 2005 A1
20050274383 Brain Dec 2005 A1
20060081245 Gould Apr 2006 A1
20060207601 Nasir Sep 2006 A1
20070137651 Glassenberg et al. Jun 2007 A1
20080099026 Chang May 2008 A1
20080142017 Brain Jun 2008 A1
20080236590 Reissmann Oct 2008 A1
20080257356 Swick Oct 2008 A1
20080276932 Bassoul Nov 2008 A1
20080308109 Brain Dec 2008 A1
20090090356 Cook Apr 2009 A1
20090247868 Chesnin Oct 2009 A1
20100059061 Brain Mar 2010 A1
20100089393 Brain Apr 2010 A1
20100126512 Nasir May 2010 A1
20100147309 Cuevas et al. Jun 2010 A1
20100242957 Fortuna Sep 2010 A1
20100319704 Nasir Dec 2010 A1
20110004197 Sansoucy Jan 2011 A1
20110023890 Baska Feb 2011 A1
20110120474 Daugherty May 2011 A1
20110226256 Dubach Sep 2011 A1
20110265799 Lisogurski Nov 2011 A1
20110277772 Nasir Nov 2011 A1
20120024292 Sandmore et al. Feb 2012 A1
20130092172 Nasir Apr 2013 A1
20130247917 Brain Sep 2013 A1
20130269689 Brain Oct 2013 A1
20130324798 Molnar Dec 2013 A1
20140171855 Mastri Jun 2014 A1
20150000672 Jassell Jan 2015 A1
20150005743 McCullough Jan 2015 A1
20150144134 Dubach May 2015 A1
20150320962 Bafile Nov 2015 A1
20160235934 Poulsen Aug 2016 A1
20160317768 Nasir et al. Nov 2016 A1
20160331918 Nasir Nov 2016 A1
20170043111 Hoftman Feb 2017 A1
20170072154 Hoftman Mar 2017 A1
20180221051 Durkin Aug 2018 A1
Foreign Referenced Citations (104)
Number Date Country
B-5203690 Sep 1990 AU
B-4580393 Feb 1994 AU
200076743 May 2001 AU
1 324 551 Nov 1993 CA
2 191 749 Dec 1995 CA
2 346 248 Apr 2000 CA
1 351 509 May 2002 CN
05251091 Jan 2016 CN
43 30 032 Apr 1994 DE
299 02 267 Jul 1999 DE
102008052752 Apr 2010 DE
000067210-0001 Aug 2003 EM
000067210-0002 Aug 2003 EM
000197124-0001 Jun 2004 EM
000197124-0002 Jun 2004 EM
000197124-0003 Jun 2004 EM
000197124-0004 Jun 2004 EM
000197124-0005 Jun 2004 EM
000197124-0006 Jun 2004 EM
000180757-0001 Jul 2004 EM
000482195-0001 Feb 2006 EM
000482195-0002 Feb 2006 EM
0 277 797 Aug 1988 EP
0 389 272 Sep 1990 EP
0 448 878 Oct 1991 EP
0 586 717 Mar 1994 EP
0 794 807 Sep 1997 EP
0 834 331 Aug 1998 EP
0 857 492 Aug 1998 EP
0 875 260 Nov 1998 EP
0 884 061 Dec 1998 EP
0 911 049 Apr 1999 EP
0 935 971 Aug 1999 EP
1 125 595 Aug 2001 EP
1504870 Feb 2005 EP
1 579 885 Sep 2005 EP
1220701 Mar 2007 EP
1169077 Dec 2007 EP
1 875 937 Jan 2008 EP
2 690 108 Oct 1993 FR
2 807 307 Oct 2001 FR
2 827 482 Jan 2003 FR
2 851 107 Aug 2004 FR
1 402 255 Aug 1975 GB
2 113 348 Aug 1983 GB
2 128 561 May 1984 GB
2 168 256 Jun 1986 GB
2 249 959 May 1992 GB
2 267 034 Nov 1993 GB
2 285 765 Jul 1995 GB
2 317 342 Mar 1998 GB
2 319 182 May 1998 GB
2 323 292 Sep 1998 GB
2 326 009 Dec 1998 GB
2 330 312 Apr 1999 GB
2 337 020 Nov 1999 GB
2 359 996 Sep 2001 GB
2 364 644 Feb 2002 GB
2 373 188 Sep 2002 GB
2 393 399 Mar 2004 GB
2 404 863 Feb 2005 GB
2 413 963 Nov 2005 GB
2438799 Dec 2007 GB
2 465 453 May 2010 GB
2465453 May 2010 GB
2479823 Oct 2011 GB
2481538 Dec 2011 GB
2481538 Dec 2011 GB
2521375 Jun 2015 GB
132546167 Jul 2017 GB
922073 Dec 1993 IE
6277286 Oct 1994 JP
2706567 Jan 1998 JP
2007-509154 Apr 2007 JP
224047 Nov 2004 TW
WO9112844 Sep 1991 WO
WO 9417848 Aug 1994 WO
WO 9712640 Apr 1997 WO
WO 9824498 Jun 1998 WO
WO 9850096 Nov 1998 WO
WO 9944665 Sep 1999 WO
WO 0009189 Feb 2000 WO
WO 0030706 Jun 2000 WO
WO 0061213 Oct 2000 WO
WO 0112844 Feb 2001 WO
WO 0113980 Mar 2001 WO
WO 2011131974 Oct 2001 WO
WO 0197890 Dec 2001 WO
WO 0232490 Apr 2002 WO
WO 03020340 Mar 2003 WO
WO 03018094 Mar 2003 WO
WO 2004016308 Feb 2004 WO
02004089453 Oct 2004 WO
WO 2005016427 Feb 2005 WO
WO2005027999 Mar 2005 WO
WO 2005041864 May 2005 WO
WO2005099800 Oct 2005 WO
WO2006125986 Nov 2006 WO
WO 2009129081 Oct 2009 WO
WO 2009142821 Nov 2009 WO
WO 2011161473 Dec 2011 WO
WO 2014058840 Apr 2014 WO
WO 2014159522 Oct 2014 WO
WO2015092404 Jun 2015 WO
Non-Patent Literature Citations (105)
Entry
Great Britain Combined Search and Examination Report issued in application No. GB1800914.2, dated Feb. 2, 2018 (6 pgs).
Notice of Allowance issued in U.S. Appl. No. 14/375,109, dated Feb. 9, 2018 (8 pgs).
Office Action issued in U.S. Appl. No. 14/375,109, dated Dec. 15, 2017 (17 pgs).
Office Action issued in U.S. Appl. No. 29/548,655, dated Mar. 8, 2018, (7 pgs).
“The Development of the Laryngeal Mask—a Brief History of the Invention, Early Clinical Studies and Experimental Work from Which the Laryngeal Mask Evolved” A.I.J. Brain, European Journal of Anesthesiology, 1991, Supplement 4, pp. 5-17.
Combined Search and Examination Report issued in corresponding application No. GB1110775.2, dated Oct. 18, 2011 (8 pgs).
Combined Search and Examination Report issued in corresponding application No. GB0718849.3, dated Oct. 29, 2007 (4 pgs).
Combined Search and Examination Report issued in corresponding application No. GB0502519.2, dated Sep. 13, 2005 (6 pgs).
Combined Search and Examination Report issued in corresponding application No. GB1019839.8, dated Dec. 1, 2010 (2 pgs).
Combined Search and Examination Report issued in corresponding application No. GB 0418050.1, dated Nov. 29, 2004 (7 pgs).
Combined Search and Examination Report issued in related application No. GB1301478.2, dated May 23, 2013 (5 pgs).
Examination Report issued in corresponding application No. 09 756 353.0-1257, dated Aug. 17, 2012 (5 pgs).
Extended European Search Report and Written Opinion issued in corresponding EPO application No. 07019251.3, dated Feb. 1, 2008 (8 pgs).
First Office Action issued in corresponding Chinese application No. 200480023382.4, dated Aug. 22, 2008 (15 pgs).
Further examination as result of telephone conversation with examiner issued in corresponding EPO application No. 03 787 902.0 (1 pg).
Great Britain Combined Search and Examination Report issued in application No. GB1322330.0, dated May 20, 2015 (8 pgs).
Great Britain Combined Search and Examination Report issued in application No. GB1322328.4, dated Feb. 26, 2015 (8 pgs).
International Preliminary Report on Patentability issued in application No. PCT/GB2014/053744, dated Jun. 21, 2016 (9 pgs).
International Search Report and Written Opinion issued in Applicant's corresponding UK Patent Application Serial No. GB0817776.8, dated Jan. 8, 2009 (6 pgs).
International Search Report and Written Opinion issued in application No. PCT/GB2014/053745, dated Mar. 11, 2015 (14 pgs).
International Search Report and Written Opinion issued in application No. PCT/GB2014/053744, dated Jul. 14, 2015 (15 pgs).
International Search Report and Written Opinion issued in corresponding application No. PCT/GB2011/051203, dated Jul. 12, 2011 (14 pgs).
International Search Report and Written Opinion issued in corresponding application No. PCT/GB2011/051203, dated Dec. 7, 2011 (15 pgs).
International Search Report and Written Opinion issued in corresponding PCT application No. PCT/GB2009/051574, dated Jun. 7, 2010 (28 pgs).
International Search Report and Written Opinion issued in related application No. PCT/GB2013/050180, dated May 7, 2013 (13 pgs).
International Search Report issued in corresponding PCT application PCT/GB03/03577 dated Aug. 14, 2003 (9 pgs).
Invitation to Pay Additional Fees with International Search Report issued in corresponding application No. PCT/GB2004/003481, dated Nov. 12, 2004 (8 pgs).
Notice for Reasons for Rejection issued in corresponding Japanese application No. 2006/523053, dated Nov. 8, 2010, with English translation (4 pgs).
Notice of Allowance issued in U.S. Appl. No. 13/805,956, dated Dec. 21, 2015 (26 pgs).
Notice of Allowance issued in U.S. Appl. No. 14/315,141, dated Nov. 13, 2015 (36 pgs).
Notice of Allowance issued in U.S. Appl. No. 14/315,149 , dated Mar. 11, 2016 (42 pgs).
Notice of Allowance issued in U.S. Appl. No. 29/428,284, dated Mar. 8, 2016 (17 pgs).
Notice of Allowance issued in related U.S. Appl. No. 13/403,806, dated Mar. 12, 2014 (16 pgs).
Notice of Allowance issued in related U.S. Appl. No. 29/416,561, dated May 9, 2014 (7 pgs).
Notice of Allowance issued in related U.S. Appl. No. 29/449,900, dated Jul. 24, 2013 (11 pgs).
Notice of Allowance issued in related U.S. Appl. No. 29/407,461, dated Jun. 12, 2013 (26 pgs).
Office Action issued in U.S. Appl. No. 12/627,844, dated May 5, 2016 (33 pgs).
Office Action issued in U.S. Appl. No. 12/627,844, dated Sep. 17, 2015 (26 pgs).
Office Action issued in U.S. Appl. No. 29/353,658 dated Aug. 19, 2011 (10 pgs).
Office Action issued in U.S. Appl. No. 29/428,284, dated Mar. 19, 2015 (6 pgs).
Office Action issued in U.S. Appl. No. 29/428,284, dated Nov. 10, 2015 (5 pgs).
Office Action issued in U.S. Appl. No. 29/512,931, dated Mar. 8, 2016 (8 pgs).
Office Action issued in U.S. Appl. No. 29/51.2,931, dated Nov. 23, 2015 (20 pgs).
Office Action issued in U.S. Appl. No. 29/512,932, dated Mar. 8, 2016 (8 pgs).
Office Action issued in U.S. Appl. No. 29/512,932, dated Nov. 19, 2015 (19 pgs).
Office Action issued in related U.S. Appl. No. 12/627,844, dated Feb. 28, 2014 (22 pgs).
Office Action issued in related U.S. Appl. No. 12/627,844, dated Oct. 23, 2014 (38 pgs).
Office Action issued in related U.S. Appl. No. 13/130,555, dated Jun. 20, 2014 (36 pgs).
Office Action issued in related U.S. Appl. No. 13/403,806, dated Apr. 25, 2013 (6 pgs).
Office Action issued in related U.S. Appl. No. 13/403,806, dated Aug. 15, 2013 (45 pgs).
Office Action issued in related U.S. Appl. No. 29/428,284, dated Oct. 6, 2014 (66 pgs).
Office Action issued in related U.S. Appl. No. 29/475,489, dated Jun. 20, 2014 (25 pgs).
Office Action issued in related U.S. Appl. No. 29/475,489, dated Dec. 4, 2014 (13 pgs).
PCT International Search Report, PCT Application Serial No. PCT/GB2008/050880, dated Jan. 14, 2009 (20 pgs).
U.S. Official Action dated Feb. 14, 2013, issued in U.S. Appl. No. 29/407,461 (21 pgs).
U.S. Appl. No. 12/627,844, filed Nov. 30, 2009, Nasir.
U.S. Appl. No. 14/375,109, filed Jul. 28, 2014, Jassell et al.
U.S. Appl. No. 29/548,655, filed Dec. 15, 2015, Miller et al.
Office Action issued in U.S. Appl. No. 14/375,109, dated Nov. 7, 2016 (17 pgs).
Office Action issued in U.S. Appl. No. 12/627,844, dated Jan. 27, 2017 (28 pgs).
Great Britain Combined Search and Examination Report Issued in Corresponding Application No. GB1621321.7, dated May 4, 2017 (5 Pages).
Great Britain Examination Report Issued in Corresponding Application No. GB1322330.0, dated Mar. 8, 2016 (3 Pages).
European Patent Office Examination Report Issued in Corresponding Application No. 14824070.8, dated Apr. 24, 2017 (9 Pages).
Official Action issued in U.S. Appl. No. 14/375,109, dated Jun. 23, 2017 (10 pgs).
U.S. Appl. No. 29/428,284, filed Jul. 27, 2012, Nasir et al.
U.S. Appl. No. 14/315,149, filed Jun. 25, 2014, Nasir.
U.S. Appl. No. 29/512,931, filed Dec. 23, 2014, Nasir et al.
U.S. Appl. No. 29/512,932, filed Dec. 23, 2014, Nasir et al.
Office Action issued in U.S. Appl. No. 14/375,109, dated Aug. 10, 2016 (49 pgs).
Notice of Allowance issued in U.S. Appl. No. 14/315,149, dated Aug. 30, 2016 (16 pgs).
Notice of Allowance issued in U.S. Appl. No. 29/548,655, dated Oct. 11, 2018 (28 pgs).
Great Britain Search and Examination Report issued in application No. GBP7665X, dated May 31, 2019 (7 pgs).
Great Britain Search and Examination Report issued in application No. GBP7665, dated May 1, 2019 (9 pgs).
Merriam-Webster Lumen Definition (Year: 2019) (1 pg).
Office Action issued in U.S. Appl. No. 15/106,243, dated Aug. 2, 2019 (18 pgs).
Action issued in U.S. Appl. No. 29/676,952, dated Jun. 6, 2019 (22 pgs).
U.S. Appl. No. 10/983,199, filed Nov. 5, 2004.
U.S. Appl. No. 10/568,362, filed Feb. 14, 2006.
U.S. Appl. No. 12/627,844, filed Nov. 30, 2009.
U.S. Appl. No. 29/353,658, filed Jan. 12, 2010.
U.S. Appl. No. 12/680,731, filed Mar. 29, 2010.
U.S. Appl. No. 12/859,169, filed Aug. 18, 2010.
U.S. Appl. No. 13/130,555, filed May 20, 2011.
U.S. Appl. No. 29/402,009, filed Sep. 19, 2011.
U.S. Appl. No. 29/407,461, filed Nov. 29, 2011.
U.S. Appl. No. 13/403,806, filed Feb. 23, 2012.
U.S. Appl. No. 29/416,561, filed Mar. 23, 2012.
U.S. Appl. No. 29/428,284, filed Jul. 27, 2012.
U.S. Appl. No. 13/805,956, filed Dec. 20, 2012.
U.S. Appl. No. 29/449,900, filed Mar. 15, 2013.
U.S. Appl. No. 29/475,489, filed Dec. 3, 2013.
U.S. Appl. No. 14/315,141, filed Jun. 25, 2014.
U.S. Appl. No. 14/315,149, filed Jun. 25, 2014.
U.S. Appl. No. 14/375,109, filed Jul. 28, 2014.
U.S. Appl. No. 29/512,931, filed Dec. 23, 2014.
U.S. Appl. No. 29/512,932, filed Dec. 23, 2014.
U.S. Appl. No. 29/548,655, filed Dec. 15, 2015.
U.S. Appl. No. 15/106,243, filed Jun. 17, 2016.
U.S. Appl. No. 29/676,952, filed Jan. 16, 2019.
U.S. Appl. No. 29/698,547, filed Jul. 17, 2019.
U.S. Appl. No. 15/106,243, filed Jun. 17, 2016, Nasir et al.
U.S. Appl. No. 29/676,952, filed Jan. 16, 2019, Miller et al.
U.S. Appl. No. 29/698,547, filed Jul. 17, 2019, Nasir et al.
Notice of Allowance issued in U.S. Appl. No. 29/676,952, dated Nov. 5, 2019 (5 pgs).
Office Action issued in U.S. Appl. No. 15/106,243, dated Jan. 10, 2020 (23 pgs).
Related Publications (1)
Number Date Country
20160331918 A1 Nov 2016 US